{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:09:21Z","timestamp":1790438961609,"version":"4.1.0"},"reference-count":35,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"German Federal Ministry of Health","award":["Global Health Protection Programme (GHPP), Projec"],"award-info":[{"award-number":["Global Health Protection Programme (GHPP), Projec"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,3,18]]},"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Lassa fever (LF) is a severe and often fatal systemic disease in humans and affects a large number of countries in West Africa. Treatment options are limited to supportive care and the broad-spectrum antiviral agent ribavirin. However, evidence for ribavirin efficacy in patients with LF is poor and pharmacokinetic (PK) data are not available.<\/jats:p>\n                    <jats:p>Irrua Specialist Teaching Hospital (ISTH) developed an intravenous ribavirin regimen different to the WHO recommendation. Apart from a lower total daily dose the drug is usually administered once per day which reduces the exposure of personnel to patients with LF. The aim of this study is to characterise the PK of the Irrua ribavirin regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This prospective, observational clinical study will assess PK properties of the Irrua ribavirin regimen on routinely ribavirin-treated patients with LF at ISTH, a referral hospital serving 19 local governmental areas in a LF endemic zone in Nigeria. Participants will be adults with PCR-confirmed LF. The primary objective is to describe classical PK parameters for ribavirin (maximum plasma drug concentration, time to maximum plasma drug concentration, area under the plasma drug concentration vs time curve, half-life time T1\/2, volume of distribution). Blood samples will be collected at 0.5, 1, 3, 5, 8, 12 and 24\u2009hours after doses on day 1, day 4 and day 10 of ribavirin treatment. Ribavirin plasma concentrations will be determined using liquid chromatography coupled to tandem mass spectrometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The study will be conducted in compliance with the protocol, the Declaration of Helsinki, Good Clinical Practice (GCP) and the Nigerian National Code for Health Research Ethics. The protocol has received approval by the Health Research Ethics Committee of ISTH. Results will be made available to LF survivors, their caregivers, the funders, LF research society and other researchers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration details<\/jats:title>\n                    <jats:p>ISRCTN11104750<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-036936","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T07:01:14Z","timestamp":1587106874000},"page":"e036936","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria"],"prefix":"10.1136","volume":"10","author":[{"given":"Cyril","family":"Erameh","sequence":"first","affiliation":[{"name":"Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria"},{"name":"Department of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osahogie","family":"Edeawe","sequence":"additional","affiliation":[{"name":"Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Akhideno","sequence":"additional","affiliation":[{"name":"Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria"},{"name":"Department of Medicine, Irrua Specialist Teaching Hospital, Irrua, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Eifediyi","sequence":"additional","affiliation":[{"name":"Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till F","family":"Omansen","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Sarpong","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Koch","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wicha","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, University of Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3807-473X","authenticated-orcid":false,"given":"Florian","family":"Kurth","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"},{"name":"Department of Infectious Diseases and Pulmonary Medicine, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Duraffour","sequence":"additional","affiliation":[{"name":"Department of Virology, Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Oestereich","sequence":"additional","affiliation":[{"name":"Department of Virology, Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meike","family":"Pahlmann","sequence":"additional","affiliation":[{"name":"Department of Virology, Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvanus","family":"Okogbenin","sequence":"additional","affiliation":[{"name":"Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria"},{"name":"Department of Obstetrics and Gynaecology, Irrua Specialist Teaching Hospital, Irrua, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim","family":"Ogbaini-Emovon","sequence":"additional","affiliation":[{"name":"Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6562-0230","authenticated-orcid":false,"given":"Stephan","family":"G\u00fcnther","sequence":"additional","affiliation":[{"name":"Department of Virology, Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ramharter","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Groger","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine, Bernhard Nocht Institute for Tropical Medicine & I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"2025121300040698000_10.4.e036936.1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.1970.19.670"},{"key":"2025121300040698000_10.4.e036936.2","doi-asserted-by":"publisher","DOI":"10.1126\/science.185.4147.263"},{"key":"2025121300040698000_10.4.e036936.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7009.857"},{"key":"2025121300040698000_10.4.e036936.4","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.3.445"},{"key":"2025121300040698000_10.4.e036936.5","doi-asserted-by":"publisher","DOI":"10.1089\/15303660160025903"},{"key":"2025121300040698000_10.4.e036936.6","doi-asserted-by":"crossref","first-page":"S783","DOI":"10.1093\/clinids\/11.Supplement_4.S783","article-title":"Clinical features of Lassa fever in Liberia","volume":"11 Suppl 4","author":"Frame","year":"1989","journal-title":"Rev Infect Dis"},{"key":"2025121300040698000_10.4.e036936.7","doi-asserted-by":"crossref","first-page":"401","DOI":"10.4269\/ajtmh.1986.35.401","article-title":"Lassa virus hepatitis: a study of fatal Lassa fever in humans","volume":"35","author":"McCormick","year":"1986","journal-title":"Am J Trop Med Hyg"},{"key":"2025121300040698000_10.4.e036936.8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.3.456"},{"key":"2025121300040698000_10.4.e036936.9","first-page":"197","article-title":"Lassa fever encephalopathy: clinical and laboratory findings","volume":"95","author":"Cummins","year":"1992","journal-title":"J Trop Med Hyg"},{"key":"2025121300040698000_10.4.e036936.10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0001839"},{"key":"2025121300040698000_10.4.e036936.11","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)30432-X","article-title":"Lassa fever in Nigeria: the great unknown","volume":"391","author":"Burki","year":"2018","journal-title":"Lancet"},{"key":"2025121300040698000_10.4.e036936.12","unstructured":"World Health Organisation . A research and development blueprint for action to prevent epidemics, 2018. Available: http:\/\/www.who.int\/blueprint\/en\/ [Accessed 27 Jul 2018]."},{"key":"2025121300040698000_10.4.e036936.13","unstructured":"World Health Organisation . Lassa fever \u2013 Nigeria, 2018. Available: http:\/\/www.who.int\/csr\/don\/20-april-2018-lassa-fever-nigeria\/en\/ [Accessed 07 May 2018]."},{"key":"2025121300040698000_10.4.e036936.14","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01891-10"},{"key":"2025121300040698000_10.4.e036936.15","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02351-09"},{"key":"2025121300040698000_10.4.e036936.16","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/141.5.580"},{"key":"2025121300040698000_10.4.e036936.17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/149.3.420"},{"key":"2025121300040698000_10.4.e036936.18","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0140-6736(79)90790-6","article-title":"Experimental Lassa fever virus infection successfully treated with ribavirin","volume":"1","author":"Stephen","year":"1979","journal-title":"Lancet"},{"key":"2025121300040698000_10.4.e036936.19","first-page":"151","article-title":"[Comparative evaluation of the antiviral efficacy of virazole and ribamidil in experimental Lassa fever in monkeys]","volume":"35","author":"Dvoretskaia","year":"1990","journal-title":"Vopr Virusol"},{"key":"2025121300040698000_10.4.e036936.20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.111085598"},{"key":"2025121300040698000_10.4.e036936.21","doi-asserted-by":"publisher","DOI":"10.1038\/82191"},{"key":"2025121300040698000_10.4.e036936.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601023140104"},{"key":"2025121300040698000_10.4.e036936.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2019.07.015"},{"key":"2025121300040698000_10.4.e036936.24","unstructured":"World Health Organisation . Application for inclusion of ribavirin in the WHO model list of essential medicines 2006."},{"key":"2025121300040698000_10.4.e036936.25","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.10.2451"},{"key":"2025121300040698000_10.4.e036936.26","first-page":"17","article-title":"The clinical pharmacology of ribavirin","volume":"19","author":"Glue","year":"1999","journal-title":"Semin Liver Dis"},{"key":"2025121300040698000_10.4.e036936.27","unstructured":"Nigeria Centre for Disease Control . National guidelines for Lassa fever cases management 2018;13."},{"key":"2025121300040698000_10.4.e036936.28","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv522"},{"key":"2025121300040698000_10.4.e036936.29","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9368-z"},{"key":"2025121300040698000_10.4.e036936.30","unstructured":"CMRC . Maximum allowable total blood draw volumes 2006."},{"key":"2025121300040698000_10.4.e036936.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005389"},{"key":"2025121300040698000_10.4.e036936.32","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchromb.2007.05.039","article-title":"Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection","volume":"856","author":"Loregian","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2025121300040698000_10.4.e036936.33","unstructured":"World Health Organization . Guidance on regulations for the transport of infectious substances 2009-2010, 2008."},{"key":"2025121300040698000_10.4.e036936.34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/psp4.8","article-title":"A model-based illustrative exploratory approach to optimize the dosing of Peg-IFN\/RBV in cirrhotic hepatitis C patients treated with triple therapy","volume":"4","author":"Laou\u00e9nan","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025121300040698000_10.4.e036936.35","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/psp4.12197","article-title":"Translational pharmacometric evaluation of typical antibiotic broad-spectrum combination therapies against Staphylococcus aureus exploiting in vitro information","volume":"6","author":"Wicha","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-036936","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T08:04:14Z","timestamp":1765613054000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-036936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,4,16]]},"published-print":{"date-parts":[[2020,4]]}},"alternative-id":["10.1136\/bmjopen-2020-036936"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-036936","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}